Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer

British Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 342-349

  Takahashi, T ^a   Cao, J ^a   Hoon, D S B ^a   Irie, R F ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; CTL; HLA; Peptide; Rb protein; RBP 1

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA A3 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7; PEPTIDE; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; EPIDERMIS CELL; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOBLASTOID CELL; MELANOMA CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CARRIER PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; RETINOBLASTOMA PROTEIN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032855532     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690698     Document Type: Article

References (31)

1. Bookstein R, Shew JY, Chen PL, Scully P and Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715
2. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P and Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365
3. Cao J-N, Gao T, Giuliano AE and Irie RF (1999) Recognition of an epitope of a breast cancer antigen by human antibody. Breast Cancer Res Treat 53: 279-290
4. Celis E, Fikes J, Wentworth P, Sidney J, Southwood S, Maewal A, Del Guercio M-F, Sette A and Livingston B (1994a) Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol 31: 1423-1430
5. Celis E, Tsai V, Crimt C, De Mars R, Wentworth PA, Chesnut RW, Grey HM, Sette A and Serra HM (1994b) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105-2109
6. Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE and Oliff A (1991) Cloning of cDNA for cellular proteins that bind to the retinoblastoma gene product. Nature 352: 251-254
7. Fattacy AR, Helin K, Dembski MS, Dyson N, Harlow E, Vuocolo GA, Hanobik MG, Haskell KM, Oliff A, Defeo-Jones D and Jones RE (1993) Characterization of the retinoblastoma binding proletein RBP1 and RBP2. Oncogene 8: 3149-3156
8. Germain RN (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T-lymphocyte activation. Cell 76: 287-299
9. Gnjatic S, Bressae-de Paillerets B, Guillet JG and Choppin J (1995) Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules Eur J Immunol 25: 1638-1642
10. Heemels MT and Ploegh H (1995) Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64; 463-491
11. Hesketh R (ed) (1997) The Oncogene and Tumor Suppressor Gene Facts Books, 2nd edn. pp 466-475. Academic Press: London
12. Hoon DSB, Okamoto T, Wang HJ, Elashoff R, Nizze JA, Foshag LJ, Gammon G and Morton DL (1998) Is the survival of melanoma patients receiving polyvalent metanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16: 1430-1437
13. Huang S, Lee WH and Lee EY (1991) A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. Nuture 350: 160-162
14. Kaelin WG Jr, Pallas DC, DeCaprio JA, Kaye FJ and Livingston DM (1991) Identification of cellular proteins that can interact specifically with the T/EIA-binding region of the retinoblastoma gene product. Cell 64: 521-532
15. Kaelin WG Jr, Krek W, Sellers WR, DeCarpio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, Livingston DM and Flemington EK (1992) Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70: 351-364
16. Kawakami Y, Eliyahu S, Aakaguchi K, Robbins PF, Rivoltini L, Yanelli JR, Appela E and Roseberg SA (1994) Identification of the immunodommant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A-2-restricted tumor infiltrating lymphocytes. J Exp Med180: 347-352
17. Lee EYP, To H, Shew JY, Bookstein R, Scully P und Lee WH (1988) Inactivation of the retinoblastoma susceptibility gene in human breast cancer. Science 241: 218-221
18. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY and Lee EYP (1987) Human retinoblastoma susceptibility gene: cloning, identification, and sequence Science 235: 1394-1399
19. Morioka N, Kikumoto Y, Hoon DSB, Morton DL and Irie RF (1994) A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 153: 5650-5658
20. Nijman HW, Van der Burg SH, Vierboom MPM, Houbiers JGA, Kast WM and Melief CJM (1994) p53, a potential target for tumor-directed T cells. Immunol Lett 40; 171-178
21. Otterson GA, Kratzke RA, Lin AY, Johnson PG and Kaye FJ (1993) Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites. Oncogene 8: 949-957
22. Peace DJ, Smith JW, Chen W, You SG, Cosand WL, Blake J and Cheever MA (1994) Lysis of ras oncogen-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 179; 473-179
23. + ovarian cancers. J Immunol 152: 4993-4999
24. Rammensee H-G, Friede T and Stevanovic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228
25. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PE, Marincola FM, Salgaller ML, Yannelli JR, Appella E and Rosenberg SA (1995) Induction of tumor-reactive CTL from peripheral blood and tumor-infiltraling lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154: 2257-2265
26. Sidney J, Grey HM, Kubo RT and Sette A (1996) Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17: 261-266
27. Takahashi T, Irie RF, Morton DL and Hoon DSB (1997a) Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. Cell Immunol 178: 162-171
28. Takahashi T, Irie RF, Nishinaka Y and Hoon DSB (1997b) 707-AP peptide recognized by human antibody induces HLA-A2 restricted CTL killing of melanoma. Clin Cancer Res 3: 1363-1370
29. Traversari C, Van der Bruggen P, Luescher IE, Lurguin C, Chomez P, Val Pel A, De Plaen E, Amar-Costesec A and Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-AI by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176; 1453-1457
30. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJM and Schrier PI (1995) Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A †0201. Int J Cancer 61: 389-396
31. Wiman KG (1993) The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB 17: 841-845